08:59 AM EDT, 04/02/2026 (MT Newswires) -- Health care stocks were declining premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.6% lower and the iShares Biotechnology ETF (IBB) down 1.6%.

Immunovant ( IMVT ) shares were down more than 8% after the company said topline results from two phase 3 clinical studies of batoclimab as an experimental treatment of thyroid eye disease in adults showed that they failed to meet their primary endpoint.